Antiepileptic Drugs Global Market Report 2025

The antiepileptic drugs market size has grown strongly in recent years. It will grow from $17.01 billion in 2024 to $18.0 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth during the historic period can be linked to the increasing prevalence of epilepsy, heightened awareness of neurological disorders, progress in drug development, government support and funding for epilepsy research, and the expansion of healthcare infrastructure in emerging markets.

The antiepileptic drugs market size is expected to see strong growth in the next few years. It will grow to $22.27 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The anticipated growth in the forecast period is driven by a rising number of patients with drug-resistant epilepsy, advancements in personalized medicine for epilepsy treatment, increased adoption of biologics and gene therapies, growing investments in epilepsy research and development, and improvements in diagnostics that enhance the identification of epilepsy cases. Key trends expected during this period include the advancement of personalized treatment approaches, progress in combination therapies for drug-resistant epilepsy, emerging therapies targeting specific genetic mutations, a stronger focus on developing safer and more effective antiepileptic drugs (AEDs), and expanded use of cannabidiol-based therapies for seizure control.

The rising prevalence of epilepsy is expected to drive the growth of the antiepileptic drugs market in the coming years. Epilepsy is a neurological disorder marked by recurrent, unprovoked seizures caused by abnormal electrical activity in the brain. An increase in head injuries from accidents contributes to a higher risk of developing epilepsy due to brain trauma and neural damage. Antiepileptic drugs (AEDs) work by stabilizing brain activity through modulation of neurotransmitters and ion channels to prevent excessive neuron firing. These drugs reduce both the frequency and severity of seizures, thereby improving the quality of life for people with epilepsy. For example, in February 2022, Epilepsy Action, a UK-based charity that supports individuals with epilepsy, reported that approximately 630,000 people in the UK live with epilepsy - about one in every 100 people - with 80 new cases diagnosed daily. Thus, the growing prevalence of epilepsy is contributing to the expansion of the antiepileptic drug market.

Leading companies in the antiepileptic drugs market are focusing on developing advanced formulations, such as intravenous (IV) antiepileptic drugs, to provide more effective treatment options for acute seizures and emergency situations. IV antiepileptic drugs are fast-acting medications administered directly into the bloodstream via injection or infusion, offering rapid seizure control, especially in emergencies or when oral medications are not suitable or effective. For instance, in January 2024, Eisai Co., Ltd., a Japan-based pharmaceutical firm, received manufacturing and marketing approval for Fycompa in Japan. Fycompa is a first-in-class, highly selective, non-competitive AMPA receptor antagonist that decreases neuronal hyper-excitation linked to seizures by targeting glutamate activity at AMPA receptors. The intravenous formulation was developed as an alternative for epilepsy patients who temporarily cannot take oral medication, such as during surgery, to reduce seizure risks associated with interrupted oral dosing. Fycompa is approved in over 75 countries and is used as an adjunctive treatment for partial-onset seizures and primary generalized tonic-clonic seizures in patients aged 4 years and older in Japan.

In August 2024, AbbVie, a U.S.-based biopharmaceutical company, acquired Cerevel Therapeutics for around $8.7 billion. This acquisition is intended to strengthen AbbVie’s neuroscience pipeline and enhance its capacity to develop treatments for neurological and psychiatric disorders. Cerevel Therapeutics is a U.S.-based biotechnology company specializing in the manufacture of antiepileptic drugs.

Major players in the antiepileptic drugs market are Pfizer Inc., Sanofi S.A., Novartis AG, Teva Pharmaceutical Industries Ltd., UCB S.A., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Jazz Pharmaceuticals plc, Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Amneal Pharmaceuticals Inc., Lupin Limited, Zydus Lifesciences Ltd., Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Supernus Pharmaceuticals Inc., SK Biopharmaceuticals Co. Ltd., Immedica Pharma AB, Neurelis Inc.

North America was the largest region in the antiepileptic drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in antiepileptic drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the antiepileptic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Antiepileptic drugs (AEDs) are medications used to control or prevent seizures in people with epilepsy and other neurological disorders. They work by altering neurotransmitter levels or ion channel function in the brain. By stabilizing electrical activity in the brain, AEDs help decrease both the frequency and severity of seizures.

The main categories of antiepileptic drugs include first-generation, second-generation, and third-generation AEDs. First-generation AEDs were the earliest seizure treatments and act by stabilizing brain activity, though they often come with more side effects and complex pharmacokinetics. These drugs come in various forms, including dry and liquid formulations, and can be administered through multiple routes such as oral and intravenous. They are distributed through a range of channels, including hospital pharmacies, retail pharmacies, online pharmacies, and drug stores.

The antiepileptic drugs market research report is one of a series of new reports that provides antiepileptic drugs market statistics, including the antiepileptic drugs industry global market size, regional shares, competitors with the antiepileptic drugs market share, detailed antiepileptic drugs market segments, market trends, opportunities, and any further data you may need to thrive in the antiepileptic drugs industry. This antiepileptic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The antiepileptic drugs market consists of sales of sodium channel blockers, calcium channel blockers, glutamate inhibitors, and gamma-aminobutyric acid (GABA) enhancers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.